Friday, March 13, 2015, 7:00am–8:00am Presidential Plenary  by unknown
ABSTRACTS
FRIDAY, MARCH 13, 2015,
7:00AM–8:00AM
PRESIDENTIAL PLENARY
PP.01 DEFINING THE PRACTICE OF
PANCREATODUODENECTOMY AROUND
THE WORLD
M. T. McMillan1, M. H. Sprys1, G. Malleo2, C. Bassi2,
C. M. Vollmer1
1University Of Pennsylvania Perelman School Of Medicine,
Philadelphia, PA; 2University Of Verona, Verona, VERONA
Introduction: Pancreatoduodenectomy (PD) is a techni-
cally challenging operation characterized by numerous
management decisions. We hypothesize that there is signi-
ficant variation in the contemporary global practice of
pancreatoduodenectomy.
Methods: A survey with native-language translation was
distributed to members of six international GI surgical soci-
eties (including AHPBA and IHPBA). Practice patterns and
surgical decision-making for PD were assessed. To evaluate
global variance, regions were clustered: North America,
South America/Mexico, Asia/Australia, and Europe/Africa.
Results: Surveys were completed by 864 surgeons, repre-
senting six continents and seven languages. Median age and
experience were 46 and 14 years. Surgeons performed a
median of 13 PDs in the past calendar year, and reported a
median career experience of 90, with only 54% surpassing
the published learning curve (>60). Significant regional dif-
ferences were observed for annual and career PD volumes
(P < 0.001). Only 4% of respondents practice pancreas
surgery exclusively, but 57% perform HPB surgery
only – greatest in Asia/Australia (70%, P < 0.0001). World-
wide, the preferred form of anastomotic reconstruction was
pancreaticojejunostomy (88%); however, this choice was
more common in North America compared with Europe/
Africa (97 vs. 81%, P < 0.0001). Regional variability was
also evident in terms of suture technique, stent use/type,
drain use/type/number, as well as the use of octreotide, seal-
ants, and autologous patches (P < 0.02 for all). In particular,
there were stark differences in practice between North and
South American surgeons (Table).
Conclusion: Globally, there is significant variability in the
practice of pancreatoduodenectomy. Many of these choices
contrast with established randomized evidence and may con-
tribute to variance in outcomes.
PP.02 COLORECTAL LIVER
METASTASES: DISAPPEARING LESIONS
IN THE ERA OF EOVIST
HEPATOBILIARY MAGNETIC
RESONANCE IMAGING
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Washington University In Saint Louis, Saint Louis, MO
Purpose: Prior studies show that the disappearance of
colorectal liver metastases on CT and PET does not imply
complete pathological response. Eovist MRI is known to be
the most sensitive imaging modality for liver lesions. Our
study evaluates “Disappearing Lesions” on Eovist MRI to
determine if disappearance predicts pathologic response.
Materials and Methods: Retrospective review of hepatic
resections for colorectal metastases between 01/2008 and
01/2014 was performed. Patients with pre-neoadjuvant
imaging and pre-operative Eovist MR were included. “Dis-
appearing lesions” were lesions on baseline imaging that
were not identifiable on pre-operative Eovist MRI. Complete
pathologic response was defined on pathology or by no
re-development of a lesion with 1 year follow-up if the site
was not resected. Persistent disease was defined as viable
lesions on pathology, or imaging evidence of recurrence
within 1 year.
Results: Baseline imaging and Eovist MRI was available for
24 patients. In 24 patients, 198 colorectal metastases were
identified on baseline imaging. On pre-operative Eovist MR
82 of the 194 lesions (42%) were “disappearing” lesions. At
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surgical pathology or 1 year follow-up imaging, 37 of 82
lesions (45%) demonstrated viable tumor (16) or recurrence
(21). Thirty-five of 82 lesions (43%) were nonviable at
pathology (9) or without evidence of recurrence at 1 year
(26). 10 lesions were resected, but difficult to correlate with
surgical pathology retrospectively and were indeterminate.
Conclusion: Despite the sensitivity of Eovist MR imaging,
disappearing lesions should be considered for surgical resec-
tion as 45% of disappearing lesions were viable on surgical
pathology or recurred when not resected.
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Objective: We investigated the expression of Liver Cancer
Stem Cells (LCSC) markers, CD44 and CD133, combined
with the presence of microvascular invasion (MVI); as pre-
dictors of outcomes in patients undergoing Liver Transplan-
tation (LT) for HCC.
Methods: Explanted livers from 95 patients with HCC who
underwent LT at the University of Kentucky Transplant
Center were analyzed. The expression of CD44 and CD133
was evaluated using immunofluorescence.
Results: Median age was 56 + 7 years, and 77 (81%) were
male. The most common causes of end-stage liver disease
were hepatitis C (50%) and alcoholic liver disease (41%).
Forty-one patients had lab MELD score >15. Median
follow-up was 64 months. Twenty two (23%) tumors had
MVI. Forty three (45%) tumors were positive for CD44, and
33 (34%) for CD133. Overall 1, 3, and 5 year survival rates
were 86%, 75%, and 64%, respectively. The combination of
MVI and either CD44 or CD133 positivity was associated
with significantly worse overall outcomes. The 5-year sur-
vival rate of patients with MVI alone is 51% compared to
those with MVI and CD44 or CD133 is 30% and 27.7%;
respectively (p < 0.001). Thirteen patients developed tumor
recurrence. On multivariable analysis, CD44 and CD133
expression in combination with MVI, were found to be
independent predictors of tumor recurrence and overall
patient survival (recurrence p < 0.003, OR = 8.05; p = 0.001,
OR = 9.5, survival p = 0.001, HR 3.7, p = 0.004, HR 3.2
respectively).
Conclusion: The expression of CD44 or CD133, combined
with MVI, were independent factors associated with
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Chemotherapy regimens according to National Comprehen-
sive Cancer Network (NCCN) guidelines for intrahepatic
cholangiocarcinoma (IHC) and gallbladder adenocarcinoma
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(GC) are interchangeable; however, the molecular differ-
ences driving tumorigenesis for these cancers remain poorly
defined. The present study utilized biomarker analysis of
actionable targets for IHC and GC to distinguish them and
potentially refine current treatment strategies.
217 IHC and 28 GC specimens referred to Caris Life Sci-
ences between 2009 thru 2012 were evaluated. Specific
testing by immunohistochemical analysis for 17 different
biomarkers was performed. In the collective cohort
(n = 245), actionable targets included: 95% low TS, 82% low
RMM1, and 74% low ERCC1, indicating potential suscep-
tibility to fluoropyrimidines/capecitabine, gemcitabine, and
platinum agents, respectively. Additional non-NCCN com-
pendium targets included TOPO1 (53.3% high, irinotecan),
MGMT (50.3% low, temozolomide), TOP2A (33% high,
anthracyclines), and PGP (30.1% low, taxanes). Subgroup
analysis by tumor origin demonstrated a differential
biomarker expression pattern with a higher frequency of IHC
tumors showing low levels of TS (99% vs. 72%, p < 0.0001),
and RRM1 (85% vs. 64%, p = 0.021) when compared to GC.
Conversely a greater frequency of GC demonstrated high
levels of TOPO1 (76% vs. 50%, p = 0.018) versus IHC,
indicating a potential increased benefit from irinotecan.
Biomarker analysis possesses the capacity to identify addi-
tional targets for which established agents are available. Dif-
ferences in molecular profiles of IHC and GC provide
evidence that the two are distinct diseases and require differ-
ent treatments.
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Background: Liver dome tumors are not traditionally ame-
nable to minimally invasive hepatectomy (MIH) due to
superior/central location. In order to increase the number of
lesions amenable to MIH, new approaches are needed. Addi-
tional challenges in MIH include loss of 3D visualization and
tactile perception for intraoperative guidance within the
intra-hepatic anatomy.
Methods: This video includes the use of a pre-operative 3D
virtual model and intra-operative augmented reality (AR)
navigation to facilitate trans-thoracic MIH of the liver
dome.
Results: We present a 52 year-old gentleman with a 3 cm
isolated hepatocellular carcinoma in segment 8. A trans-
thoracic approach was chosen to allow for MIH. The video
begins with presentation of 3D reconstruction and virtual
resection planning. Principles of AR are detailed. The surgi-
cal steps include positioning and triangulation of thoracic
ports under AR guidance, followed by trans-diaphragmatic
tumor localization, identification of the phrenotomy site, and
planning of margins using intra-operative ultrasound com-
bined with AR. The parenchyma is transected with bipolar
radiofrequency ablation and ultrasonic scalpel. After closure
of diaphragm, the specimen is extracted through an enlarged
thoracic port, and a chest tube is placed. The procedure was
well tolerated. The chest tube was pulled on day 3 and dis-
charge occurred on day 4.
Conclusion: This video of liver resection for challenging
tumor localization illustrates a different, safe, and valuable
approach to MIH. It highlights how 3D virtual resection
planning and AR can enhance and facilitate complex MIH,
thereby easing the transition into the minimally invasive era
for liver surgery.
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Background: Approximately 10% of pancreatic cancer
(PC) may be hereditary and screening of high risk individuals
has been recommended. Herein we describe the establish-
ment of a comprehensive multidisciplinary screening
program.
Methods: Screening criteria included the presence of PC
in: 2+ first-degree relatives (FDR), or 3+ any degree relatives
(ADR), or any known hereditary cancer syndrome with
increased PC risk. Lifetime PC risk was calculated using the
CancerGene PancPro software. The clinic provided genetic
counseling and nutrition/wellness education. MRI imaging
was selectively recommended based the lifetime PC risk.
Results: Forty-three patients were screened; 65% were
female and the median age was 54 (IQR:11). Family history
was significant for two FDR in 12 (28%) patients and three
ADR in 11 (26%). Median age of the earliest affected family
member with PC was 59 (IQR:15). Hereditary cancer syn-
dromes were present in 18 (41%) patients: BRCA1(3),
BRCA2(6), MLH1(1), PMS2(1), PALB2(1), ATM(1),
CDKN2A(4) and STK11(1). Median PancPro estimated life-
time risk of screened patients was 7% (IQR:6). Twenty-two
(51%) of 43 patients had a lifetime risk over 10%. Elevated
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